



Luxembourg, 21 March 2024

## Environmental and Social Data Sheet

### Overview

Project Name:	<i>BAYER PHARMACEUTICAL RDI</i>
Project Number:	<i>2023-0583</i>
Country:	<i>Germany</i>
Project Description:	<i>The project will support the Research &amp; Development activities of an EU-based promoter in its pharmaceutical business, related to its pharmaceutical product pipeline targeting unmet medical needs, and in particular pertain to the therapeutic areas of Cardiology, Oncology care, Ophthalmology, Women's Healthcare, Radiology as well as Cross-disease research platforms and other R&amp;D project work.</i>
EIA required:	no
Project included in Carbon Footprint Exercise <sup>1</sup> :	no

### Environmental and Social Assessment

#### Environmental Assessment

The Project concerns RDI activities that will be carried out in already existing and authorised facilities. The research and development activities of the project do not fall under either Annex I or Annex II of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

With the Project including intangible assets and digitalization components, it is considered to be aligned with both the low carbon and resilience goals and climate policy set out in the EIB Climate Bank Roadmap, i.e. research and digitalisation projects are considered:

- Paris aligned as defined in the EIB Climate Bank Roadmap (Annex 2), and;
- not materially at risk from physical climate change hazards, because they are not exposed and/or can be easily repaired or replaced in case of weather or climate related damage or loss.

#### EIB Paris Alignment for Counterparties (PATH) Framework

The counterparty is a corporate in scope and screened in to the PATH framework due to the industry being classified as a high-emitting sector. However, it is screened out for resilience due to the industry not being classified as a high vulnerability sector.

The Promoter meets the requirements of the EIB PATH framework with its existing alignment plan. The counterparty's decarbonization plan has been validated by SBTi and is aligned with the 1.5°C pathway.

#### Other Environmental and Social Aspects

The Promoter has a clear diversity and inclusion policy and initiatives in support of gender equality at all levels of the organization, including measures to accelerate the promotion of female talent and encourage an inclusive work environment.

<sup>1</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20,000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.



Luxembourg, 21 March 2024

The Promoter has a firm focus on transparency and sustainability and its ESG efforts are rated by multiple ESG rating agencies. In 2022, women accounted for more than 33% of the Promoter's Supervisory Board, 16.7% of the Promoter's Board of Management, 25% for the first and second management level below the Board of Management, and 42% of the overall workforce. The Promoter aims at full gender parity at all management levels (including the Board of Management) by 2030.

The Project does not have any significant negative social impacts. To the contrary, the project is expected to lead to significant social benefits resulting from new and improved medicines addressing unmet medical needs and in turn leading to improved quality of life for patients.

The promoter is a signatory of the UN Global Compact and produces an annual Sustainability report (covering all ESGs) aligned with the Global Reporting Initiative (GRI) in order to accelerate progress towards a net-zero economy by 2050.

## **Conclusions and Recommendations**

The Promoter has effective policies and operating procedures in place, which are in line with industry standards. The Project concerns investment in research and development which are not listed in either Annex I or Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU.

The Project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the Project is deemed to have non-significant ECS risks and impacts.

Considering the above, including the capacity of the Promoter and the overall net positive social impact, this Project is deemed acceptable for the Bank's financing under environmental and social terms.